Camrelizumab Combined With Apatinib Mesylate and TACE in the Perioperative Treatment of Hepatocellular Carcinoma
Status:
Recruiting
Trial end date:
2027-11-01
Target enrollment:
Participant gender:
Summary
Hepatocellular carcinoma (HCC) is the most common primary liver cancer. Hepatectomy is a
curable and effective method. However, the recurrence rate is as high as 50%~70% in 5 years
after surgery. Perioperative treatment with immunotherapy combined with target therapy is
expected to improve the patient's prognosis. This study aims to evaluate the efficacy, safety
and tolerability of camrelizumab combined with apatinib mesylate in the perioperative period
of resectable hepatocellular carcinoma. The primary purpose of this study is to evaluate
recurrence-free survival (RFS) of camrelizumab combined with apatinib mesylate in the
perioperative period of hepatocellular carcinoma (CNLC Ib-IIIa). The secondary research
purpose is to evaluate the R0 resection rate, the rate of subjects with major pathological
response, the rate of subjects with pathological complete response, event-free survival
(EFS), overall survival and 12-months recurrence-free survival of camrelizumab combined with
apatinib mesylate in the perioperative period of resectable hepatocellular carcinoma. The
safety and tolerability is also evaluated.
Phase:
Phase 3
Details
Lead Sponsor:
The First Affiliated Hospital with Nanjing Medical University